血管紧张素受体Ⅱ拮抗剂抗肝纤维化的近期疗效观察  

Short-term theraputic effect of angintensin Ⅱ receptor blockade on hepatic fibrosis of patients with chronic hepatitis B

作　　者：程厚文[1] 王焕云[1] 张仕岭[1] 尹迎春[1] 

机构地区：[1]泰山医学院,山东泰安271016

出　　处：《泰山医学院学报》2006年第8期704-706,共3页Journal of Taishan Medical College

摘　　要：目的研究血管紧张素受体Ⅱ拮抗剂(代文)治疗慢性乙型肝炎肝纤维化的治疗作用。方法35例慢性乙型肝炎患者随机分为代文组及复方鳖甲软肝片组,疗程为6个月,测治疗前后血清HA、HPCⅢ、LN及TGF-β1水平。结果两组治疗前后HA、HPCⅢ、LN及TGF-β1均降低(P<0.05),两组治疗后相比较血清肝纤维化指标无显著差异(P>0.05),但TGF-β1有统计学意义(P<0.05)。结论血管紧张素受体Ⅱ拮抗剂具有较好的抗乙型肝炎肝纤维化的作用。Objective： To study the changes of fibrosis serum markers and transforming growth factor betal of angintensin Ⅱ receptor blockade （Diovan） in treatment of patients with fibrosis of hepatitis B. Methods： 35 patients with chronic hepatitis B were randomly divided into group of Diovan and Fufang Biejia Ruangan Pian. Patients in both groups received conventional drugs for 6 months . Serum HA, HPC Ⅲ, LN and TGF -β1 were measured in the above patients at 0,6 months after treatment. Results ： The serum levels of HA, HPC Ⅲ, LN and TGF - β were decreased after treatment in both groups. There was no difference between two group of fibrosis serum markers , but significant difference of TGF - β1. Conclusions： Angintensin Ⅱ receptor blockade is effective in treatment of fibrosis of chronic hepatitis B.

关 键 词：血管紧张素受体Ⅱ拮抗剂 慢性乙型肝炎 肝纤维化 肝纤维化指标 转化生长因子Β 

分 类 号：R575.2[医药卫生—消化系统]